BRISBANE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) today announced that the company is scheduled to present at the Jefferies Global Healthcare Conference on Tuesday, June 3, 2014, at 1:30 p.m. ET. Donald J. Santel, chief executive officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm. About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI ® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL ® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed in ex-U.S. geographies through business partners. Upon closing of the recently announced acquisition of Andromeda Biotech Ltd., the company will also own DiaPep277 ®, a first-in-class immune intervention therapy for new onset Type 1 diabetes. For more information, please visit www.hyperiontx.com.
CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829